A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. (Q45409784)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 November 2006

Language	Label	Description	Also known as
English	A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.	scientific article published on 28 November 2006

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120 (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Per Johan Klasse

10

object named as

Per Johan Klasse

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

13

object named as

John P Moore

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

author name string

Michael Franti

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Antu K Dey

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Marc Kirschner

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Sai Prasad N Iyer

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Danielle C Fisch

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Thomas Ketas

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Eloisa Yuste

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Ronald C Desrosiers

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Paul J Maddon

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

William C Olson

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

language of work or name

0 references

publication date

28 November 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

360

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

329-340

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17126869%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Human Immunodeficiency Virus Type 1 Env with an Intersubunit Disulfide Bond Engages Coreceptors but Requires Bond Reduction after Engagement To Induce Fusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

HIV vaccine design and the neutralizing antibody problem

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

A chimeric protein of simian immunodeficiency virus envelope glycoprotein gp140 and Escherichia coli aspartate transcarbamoylase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Prospects for an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

The HIV Env-mediated fusion reaction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Prospects for an AIDS vaccine: three big questions, no easy answers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Lessons from failure--preparing for future HIV-1 vaccine efficacy trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Codon usage limitation in the expression of HIV-1 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Medicine. The need for a global HIV vaccine enterprise

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Electropermeabilization of skeletal muscle enhances gene transfer in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Maturation of HIV envelope glycoprotein precursors by cellular endoproteases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

gp120: Biologic aspects of structural features

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Effects of HIV Type 1 Envelope Glycoprotein Proteolytic Processing on Antigenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.10.032

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45409784&oldid=1378381604"